<DOC>
	<DOCNO>NCT02931565</DOCNO>
	<brief_summary>The objective study follow : In patient primary Type II Achalasia , follow single 5-mg dose IW-1701 , - To assess safety tolerability - To determine effect measure esophageal function high-resolution impedance manometry ( HRIM ) - To determine pharmacokinetic ( PK ) parameter , Cmax , Tmax , AUClast</brief_summary>
	<brief_title>Study IW-1701 , A Stimulator Soluble Guanylate Cyclase ( sGC ) , Patients With Type II Achalasia</brief_title>
	<detailed_description />
	<mesh_term>Esophageal Achalasia</mesh_term>
	<criteria>Patient male female 18 65 year old Screening Visit . Patient diagnosis primary Type II achalasia . Patient contraindication performance baseline postdose HRIM procedure per Investigator discretion . Patient prior esophageal , periesophageal , gastric surgery , prior pneumatic dilation , prior esophageal injection botulinum toxin sclerosing agent . ( Patients prior bougie dilation â‰¤ 2 cm allow ) Patients malignant premalignant esophageal lesion . Patient take drug affect GI motility 72 hour Checkin Discharge clinic . Other exclusion criterion specify protocol .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>October 2016</verification_date>
</DOC>